MX2019012435A - Formulacion farmaceutica. - Google Patents
Formulacion farmaceutica.Info
- Publication number
- MX2019012435A MX2019012435A MX2019012435A MX2019012435A MX2019012435A MX 2019012435 A MX2019012435 A MX 2019012435A MX 2019012435 A MX2019012435 A MX 2019012435A MX 2019012435 A MX2019012435 A MX 2019012435A MX 2019012435 A MX2019012435 A MX 2019012435A
- Authority
- MX
- Mexico
- Prior art keywords
- film
- opioid
- treatment
- pharmaceutical formulation
- monovalent cation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una película que comprende una sal de alginato de un catión monovalente o una mezcla de sales de alginato que contienen al menos una sal de alginato de un catión monovalente, y un antagonista de un receptor de opioide, un agonista inverso de un receptor de opioide, o un profármaco del mismo. La presente invención se refiere además a los métodos de fabricación de tal película, y al uso de la película en el tratamiento de un paciente humano, en particular el uso de tal película en el tratamiento de los efectos de la sobredosis aguda de opioides, o el uso de la película en reducción del riesgo de abuso de opioides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709141.4A GB201709141D0 (en) | 2017-06-08 | 2017-06-08 | Pharmaceutical formulation |
| PCT/EP2018/065223 WO2018224674A1 (en) | 2017-06-08 | 2018-06-08 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012435A true MX2019012435A (es) | 2020-01-13 |
Family
ID=59358417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012435A MX2019012435A (es) | 2017-06-08 | 2018-06-08 | Formulacion farmaceutica. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11219600B2 (es) |
| EP (2) | EP3932399A1 (es) |
| CN (1) | CN110831575A (es) |
| AU (1) | AU2018279192A1 (es) |
| BR (1) | BR112019025552A2 (es) |
| CA (1) | CA3056992A1 (es) |
| DK (1) | DK3634377T3 (es) |
| ES (1) | ES2881710T3 (es) |
| GB (1) | GB201709141D0 (es) |
| HR (1) | HRP20211323T1 (es) |
| HU (1) | HUE055884T2 (es) |
| IL (1) | IL271226A (es) |
| MX (1) | MX2019012435A (es) |
| PL (1) | PL3634377T3 (es) |
| PT (1) | PT3634377T (es) |
| RU (1) | RU2019139286A (es) |
| SI (1) | SI3634377T1 (es) |
| WO (1) | WO2018224674A1 (es) |
| ZA (1) | ZA201906318B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3040014A1 (en) | 2016-11-15 | 2018-05-24 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201911715D0 (en) * | 2019-08-15 | 2019-10-02 | Klaria Pharma Holding Ab | Film formulation comprising carriers |
| GB201912505D0 (en) * | 2019-08-30 | 2019-10-16 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2021158957A1 (en) * | 2020-02-05 | 2021-08-12 | Summit Biosciences Inc. | Drug products for intranasal administration and uses thereof |
| DE102021105268A1 (de) | 2021-03-04 | 2022-09-08 | Lts Lohmann Therapie-Systeme Ag. | Oraler Dünnfilm |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| US20240009184A1 (en) * | 2022-03-11 | 2024-01-11 | John Abernethy | Opioid overdose reversal mixtures |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB933462A (en) | 1958-12-17 | 1963-08-08 | Simone Marie Antoinette Radouc | Improvements in or relating to the treatment of meat |
| US5288498A (en) | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
| US5785989A (en) | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| WO1998001134A1 (en) | 1996-07-10 | 1998-01-15 | Novartis Consumer Health S.A. | Oral pharmaceutical combinations of antihistaminic compounds and terpenoids |
| ZA976189B (en) | 1996-07-12 | 1999-01-11 | Novartis Consumer Health Sa | Oral pharmaceutical combinations |
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| KR100452972B1 (ko) | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
| US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20040247649A1 (en) | 2002-02-11 | 2004-12-09 | Edizone, Lc | Medicine-containing orally soluble films |
| EP1539069A4 (en) | 2002-05-31 | 2007-11-14 | Univ Mississippi | TRANSMUCOSAL DELIVERY OF CANNABINOIDS |
| DE10226494A1 (de) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| GB0217382D0 (en) | 2002-07-26 | 2002-09-04 | Pfizer Ltd | Process for making orally consumable dosage forms |
| US9561182B2 (en) | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
| US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| RU2342953C2 (ru) | 2003-02-24 | 2009-01-10 | Фармасьютикал Продакшенз, Инк. | Трансмукозная система доставки лекарственных средств |
| US9498454B2 (en) | 2003-02-24 | 2016-11-22 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
| EP1648362A4 (en) | 2003-07-01 | 2012-01-11 | Todd Maibach | FILM CONTAINING THERAPEUTIC AGENTS |
| KR20050048056A (ko) | 2003-11-18 | 2005-05-24 | (주)케이비피 | 경구용 소모 필름 조성물 |
| US20080254108A1 (en) | 2004-08-23 | 2008-10-16 | Mark Rosenberg | Formulations and Methods for Modulating Satiety |
| NZ555501A (en) | 2004-11-24 | 2010-01-29 | Medpointe Healthcare Inc | Compositions comprising azelastine and methods of use thereof |
| WO2006095267A1 (en) | 2005-03-10 | 2006-09-14 | Institut Pasteur | Compositions for the treatment of tumour pathologies, comprising internalin b (in1b) of listeria monocytogene protein or a fragment thereof |
| CA2656961C (en) | 2005-03-15 | 2014-07-22 | Animal Ethics Pty Ltd | A topical anaesthetic composition |
| US20070059361A1 (en) | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| GB2423711B (en) | 2005-10-24 | 2007-02-14 | Fortune Apex Dev Ltd | Method for preparing a pharmaceutical composition with enhanced mucoadhesion |
| SE530184C2 (sv) | 2005-12-23 | 2008-03-18 | Kjell Stenberg | Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater |
| IL175338A0 (en) | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| CN101081218A (zh) | 2006-06-02 | 2007-12-05 | 范敏华 | 一种口腔速崩膜及其制备方法 |
| TW200815048A (en) | 2006-06-05 | 2008-04-01 | Verus Pharmaceuticals Inc | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| KR100855566B1 (ko) | 2006-09-12 | 2008-09-03 | (주) 아모젠 | 경구용 소모성 필름 |
| KR101729986B1 (ko) | 2006-09-22 | 2017-04-25 | 노보 노르디스크 에이/에스 | 프로테아제 내성 인슐린 유사체 |
| US20080269347A1 (en) | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
| AU2007333105A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| EP3542785A1 (en) | 2007-01-31 | 2019-09-25 | Rutgers, The State University of New Jersey | Controlled release of actives in skin |
| US20100215774A1 (en) | 2007-02-09 | 2010-08-26 | Todd Maibach | Film comprising nitroglycerin |
| US20090246273A1 (en) | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Ketorolac Sublingual Spray for the Treatment of Pain |
| WO2009126132A1 (en) | 2008-03-31 | 2009-10-15 | Mark Rosenberg | Formulations and methods for modulating satiety |
| CA2734381A1 (en) | 2008-09-12 | 2010-03-18 | Critical Pharmaceuticals Limited | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
| US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8900634B2 (en) | 2008-11-03 | 2014-12-02 | Nal Pharmaceuticals, Ltd. | Diethylstilbestrol dosage form and methods of treatment using thereof |
| CN101574330A (zh) | 2009-06-12 | 2009-11-11 | 上海现代药物制剂工程研究中心有限公司 | 苯甲酸利扎曲普坦膜剂 |
| KR101074271B1 (ko) | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
| US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| NZ599344A (en) | 2009-09-25 | 2015-02-27 | Reddy’S Lab Ltd Dr | Formulations comprising triptan compounds |
| KR101612073B1 (ko) | 2009-10-30 | 2016-04-14 | 아이엑스 바이오파마 리미티드 | 신속 용해 고체 투약 제형 |
| KR101077468B1 (ko) | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
| KR101303479B1 (ko) | 2011-07-28 | 2013-09-06 | (주)씨엘팜 | 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제 |
| CA2843390A1 (en) | 2011-07-29 | 2013-02-07 | Kempharm, Inc. | Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same |
| WO2013052770A1 (en) | 2011-10-05 | 2013-04-11 | Sanders Jennifer L | Methods and compositions for treating foot or hand pain |
| US20140242177A1 (en) | 2011-10-21 | 2014-08-28 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| WO2013171146A1 (en) * | 2012-05-15 | 2013-11-21 | Lts Lohmann Therapie-Systeme Ag | Oral film containing enteric release opiate resinate |
| US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
| FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
| CN102871984B (zh) | 2012-11-05 | 2015-11-11 | 天津市聚星康华医药科技有限公司 | 一种盐酸去氧肾上腺素口腔速溶膜及其制备方法 |
| CN102961365B (zh) | 2012-12-17 | 2016-01-20 | 天津市聚星康华医药科技有限公司 | 硫酸特布他林口腔速溶膜及其制备方法 |
| KR101643572B1 (ko) | 2013-03-07 | 2016-07-29 | 에스케이케미칼주식회사 | 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법 |
| WO2014160404A1 (en) | 2013-03-13 | 2014-10-02 | The Regents Of The University Of California | Improved oral drug devices and drug formulations |
| US9433589B2 (en) | 2013-06-17 | 2016-09-06 | Rigshospitalet | Injectable pharmaceutical compositions comprising adrenaline and citric acid |
| DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| US20160303040A1 (en) | 2013-11-19 | 2016-10-20 | Rigshospitalet | Injectable pharmaceutical compositions comprising prostacyclin |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| WO2015160941A1 (en) | 2014-04-15 | 2015-10-22 | Vizuri Health Sciences Llc | Topical compositions for pain relief, manufacture and use |
| US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
| US20150359738A1 (en) | 2014-06-16 | 2015-12-17 | Loewi LLC | Methods of Anesthetizing Nerve Tissue in the Trigeminal Nerve Pathway and Medical Uses Thereof |
| US10307397B2 (en) | 2014-07-28 | 2019-06-04 | Concept Matrix Solutions | Oral dissolvable film that includes plant extract |
| LT3193826T (lt) * | 2014-07-31 | 2019-01-25 | Pharmathen S.A. | Burnoje disperguojamos plėvelės kompozicija, apimanti enalaprilį, skirta hipertenzijos gydymui vaikų populiacijoje |
| US10383950B2 (en) | 2014-08-14 | 2019-08-20 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh (De/De) | Methods and compositions of carrier systems for the purpose of intracellular drug targeting |
| CN105878171A (zh) * | 2014-12-22 | 2016-08-24 | 南京海恒医药科技有限公司 | 一种依达拉奉新制剂及其制备方法 |
| WO2016161537A1 (en) | 2015-04-08 | 2016-10-13 | Maxinase Life Sciences Limited | Bioadhesive compositions for intranasal administration of granistron |
| WO2016201286A1 (en) | 2015-06-11 | 2016-12-15 | Applied Biology, Inc. | Treatment of sexual dysfunction |
| WO2017003935A1 (en) | 2015-06-27 | 2017-01-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| CA2994331C (en) | 2015-07-31 | 2023-10-03 | Delivra Inc. | Transdermal formulations for delivery of capsaicinoids |
| US10039710B2 (en) | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
| US20170079907A1 (en) | 2015-09-18 | 2017-03-23 | Insys Development Company, Inc. | Sublingual Epinephrine Spray |
| US9833461B2 (en) | 2015-10-23 | 2017-12-05 | Ctt Pharma Inc. | Therapeutic compositions comprising cannabidiol and corticosteroids |
| WO2017120492A1 (en) | 2016-01-07 | 2017-07-13 | Viramal Limited | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof |
| WO2017132410A1 (en) | 2016-01-26 | 2017-08-03 | Frank Litvack | Compositions and uses of alpha-adrenergic agents |
| WO2017135195A1 (ja) | 2016-02-03 | 2017-08-10 | 社会医療法人蘇西厚生会 まつなみリサーチパーク | アレルギー症状の予防又は治療剤 |
| US10265362B2 (en) | 2016-04-12 | 2019-04-23 | Scott Schaneville | Ingestible films having substances from hemp or cannabis |
| CA3022797A1 (en) | 2016-05-05 | 2017-11-09 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US20180125977A1 (en) | 2016-05-05 | 2018-05-10 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
| US20180104195A1 (en) | 2016-05-05 | 2018-04-19 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
| WO2017192921A1 (en) | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
| WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
| CA3040014A1 (en) | 2016-11-15 | 2018-05-24 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| CN107080745A (zh) | 2017-04-14 | 2017-08-22 | 宁夏医科大学 | 一种载叶黄素白蛋白纳米粒的口腔速溶膜及其制备方法 |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201807942D0 (en) | 2018-05-16 | 2018-06-27 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201911715D0 (en) | 2019-08-15 | 2019-10-02 | Klaria Pharma Holding Ab | Film formulation comprising carriers |
| GB201912505D0 (en) | 2019-08-30 | 2019-10-16 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| EP4054523A1 (en) | 2019-11-04 | 2022-09-14 | Maabarot Products Ltd. | Orally administrable films comprising poorly water soluble active ingredients and preparation thereof |
-
2017
- 2017-06-08 GB GBGB1709141.4A patent/GB201709141D0/en not_active Ceased
-
2018
- 2018-06-08 PT PT187296835T patent/PT3634377T/pt unknown
- 2018-06-08 RU RU2019139286A patent/RU2019139286A/ru unknown
- 2018-06-08 BR BR112019025552-4A patent/BR112019025552A2/pt unknown
- 2018-06-08 EP EP21177626.5A patent/EP3932399A1/en not_active Withdrawn
- 2018-06-08 EP EP18729683.5A patent/EP3634377B1/en active Active
- 2018-06-08 PL PL18729683T patent/PL3634377T3/pl unknown
- 2018-06-08 MX MX2019012435A patent/MX2019012435A/es unknown
- 2018-06-08 HU HUE18729683A patent/HUE055884T2/hu unknown
- 2018-06-08 DK DK18729683.5T patent/DK3634377T3/da active
- 2018-06-08 SI SI201830368T patent/SI3634377T1/sl unknown
- 2018-06-08 CA CA3056992A patent/CA3056992A1/en active Pending
- 2018-06-08 AU AU2018279192A patent/AU2018279192A1/en not_active Abandoned
- 2018-06-08 CN CN201880033877.7A patent/CN110831575A/zh active Pending
- 2018-06-08 WO PCT/EP2018/065223 patent/WO2018224674A1/en active Application Filing
- 2018-06-08 ES ES18729683T patent/ES2881710T3/es active Active
- 2018-06-08 US US16/607,892 patent/US11219600B2/en active Active
-
2019
- 2019-09-25 ZA ZA2019/06318A patent/ZA201906318B/en unknown
- 2019-12-05 IL IL271226A patent/IL271226A/en unknown
-
2021
- 2021-08-17 HR HRP20211323TT patent/HRP20211323T1/hr unknown
- 2021-12-03 US US17/457,460 patent/US11904049B2/en active Active
-
2024
- 2024-01-11 US US18/410,212 patent/US20240165022A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3634377T3 (pl) | 2021-12-20 |
| US20240165022A1 (en) | 2024-05-23 |
| SI3634377T1 (sl) | 2021-11-30 |
| ZA201906318B (en) | 2022-05-25 |
| GB201709141D0 (en) | 2017-07-26 |
| CN110831575A (zh) | 2020-02-21 |
| US20200246253A1 (en) | 2020-08-06 |
| AU2018279192A1 (en) | 2019-10-17 |
| PT3634377T (pt) | 2021-10-18 |
| HRP20211323T1 (hr) | 2021-11-26 |
| EP3634377B1 (en) | 2021-07-21 |
| WO2018224674A9 (en) | 2019-03-21 |
| US11904049B2 (en) | 2024-02-20 |
| WO2018224674A1 (en) | 2018-12-13 |
| DK3634377T3 (da) | 2021-08-30 |
| ES2881710T3 (es) | 2021-11-30 |
| HUE055884T2 (hu) | 2021-12-28 |
| US11219600B2 (en) | 2022-01-11 |
| EP3932399A1 (en) | 2022-01-05 |
| US20220160618A1 (en) | 2022-05-26 |
| RU2019139286A3 (es) | 2022-03-03 |
| EP3634377A1 (en) | 2020-04-15 |
| CA3056992A1 (en) | 2018-12-13 |
| RU2019139286A (ru) | 2021-07-09 |
| BR112019025552A2 (pt) | 2020-06-23 |
| IL271226A (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012435A (es) | Formulacion farmaceutica. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2016001793A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
| MX2013007622A (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| IN2015DN00528A (es) | ||
| NZ729252A (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| MX2019005141A (es) | Efecto protector de dmpc, dmpg, dmpc/dmpg, lisopg y lisopc contra fármacos que causan canalopatías. | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2019005160A (es) | Formulacion farmaceutica. | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2017013049A (es) | Formas de sal farmaceuticas de un inhibidor de amina oxidasa sensible a semicarbazida (ssao). | |
| MX2019004222A (es) | Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias. | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| MX2018003349A (es) | Productos de farmaco nasal y metodos de su uso. |